Newsbytes
  • India
  • Business
  • World
  • Politics
  • Sports
  • Science
  • Entertainment
  • Auto
  • Lifestyle
  • Inspirational
  • Career
  • Bengaluru
  • Delhi
  • Mumbai
  • Videos
  • Phone Reviews
  • Find Cricket Statistics
Hindi
More
Newsbytes
Hindi
Newsbytes
User Placeholder

Hi,

Logout


India
Business
World
Politics
Sports
Science
Entertainment
Auto
Lifestyle
Inspirational
Career
Bengaluru
Delhi
Mumbai
Videos
Phone Reviews
Find Cricket Statistics

More Links
  • Videos

Download Android App

Follow us on
  • Facebook
  • Twitter
  • Linkedin
  • Youtube
 
Home / News / India News / SII gets nod for Oxford COVID vaccine phase 2/3 trials
  • India

    SII gets nod for Oxford COVID vaccine phase 2/3 trials

    Siddhant Pandey
    Written by
    Siddhant Pandey
    Twitter
    Last updated on Aug 03, 2020, 10:52 am
    SII gets nod for Oxford COVID vaccine phase 2/3 trials
  • The Serum Institute of India (SII) has gotten the approval to conduct phase 2 and 3 human clinical trials of the COVID-19 vaccine candidate developed by Oxford University.

    The Drugs Controller General of India (DCGI) gave the approval to SII late Sunday night after a thorough evaluation based on the recommendations of the Subject Expert Committee.

    Here are more details.

  • In this article
    DCGI Dr. VG Somani gave nod to SII for trials Phase 2, 3 trials underway in UK SII to conduct observer-blind, randomized controlled study 1,600 people above 18 years will participate in trials SII had sent revised proposal last week
  • Details

    DCGI Dr. VG Somani gave nod to SII for trials

    DCGI Dr. VG Somani gave nod to SII for trials
  • Government officials told PTI that SII had been granted the approval to conduct phase 2 and 3 clinical trials by the DCGI Dr. VG Somani.

    A senior official said, "The firm has to submit safety data, evaluated by the Data Safety Monitoring Board, to the CDSCO before proceeding to phase 3 clinical trials."

    The SII has partnered with AstraZeneca for manufacturing Oxford's vaccine candidate.

  • Information

    Phase 2, 3 trials underway in UK

  • Already, phase 2 and 3 clinical trials of the Oxford vaccine candidate, called AZD1222 (previously known as ChAdOx1 nCoV-19), are underway in the United Kingdom. In Brazil, phase 3 clinical trials are underway while phase 1 and 2 trials continue in South Africa.

  • Trial

    SII to conduct observer-blind, randomized controlled study

    SII to conduct observer-blind, randomized controlled study
  • The official said, "As per the study design, each subject will be administered two doses four weeks apart (first dose on day one and second dose on day 29) following which the safety and immunogenicity will be assessed at predefined intervals."

    They added, "[The SII] would conduct an observer-blind, randomized controlled study to determine the safety and immunogenicity of 'Covishield' on healthy Indian adults."

  • Information

    1,600 people above 18 years will participate in trials

  • According to a revised proposal submitted by SII, 1,600 people aged above 18 years will participate in the trials across 17 selected sites, including AIIMS-Delhi, BJ Medical College in Pune, Rajendra Memorial Research Institute of Medical Sciences in Patna, PGIMER in Chandigarh, AIIMS-Jodhpur, etc.

  • Recent developments

    SII had sent revised proposal last week

    SII had sent revised proposal last week
  • The SII had submitted its first application to the DCGI on July 25 to seek approval for phase 2 and 3 clinical trials.

    The institute had then sent a revised proposal on Wednesday after it had been asked to do so, following deliberation over its application by the expert panel at the Central Drugs Standard Control Organisation (CDSCO).

  • Brazil
  • South Africa
  • Oxford
  • Vaccine
  • Oxford University
  •  
Latest News
  • Amid COVID-19 spike, Delhi schools, colleges shut until further notice
    Amid COVID-19 spike, Delhi schools, colleges shut until further notice
    India
  • Catch Sony's 'Spider-Man,' 'Venom,' 'Jumanji' on Netflix, but conditions apply
    Catch Sony's 'Spider-Man,' 'Venom,' 'Jumanji' on Netflix, but conditions apply
    Entertainment
  • IPL 2021: Chris Lynn to play for MI against RCB
    IPL 2021: Chris Lynn to play for MI against RCB
    Sports
  • Massive LinkedIn data leak affects nearly 70 percent accounts
    Massive LinkedIn data leak affects nearly 70 percent accounts
    Science
  • IPL 2021, MI vs RCB: Virat Kohli elects to field
    IPL 2021, MI vs RCB: Virat Kohli elects to field
    Sports
Related Timelines
  • Rs. 200 per vaccine dose: SII receives government's purchase order
    Rs. 200 per vaccine dose: SII receives government's purchase order
    India
  • SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    SII, Bharat Biotech ensure 'smooth roll out' of vaccines globally
    India
  • Coronavirus: 'Davai bhi, kadaai bhi,' Modi calls for sustained caution
    Coronavirus: 'Davai bhi, kadaai bhi,' Modi calls for sustained caution
    India
  • UK's approval to Oxford-AstraZeneca vaccine paves way for India
    UK's approval to Oxford-AstraZeneca vaccine paves way for India
    India
Trending Topics
ISRO Vaccine
Next News Article
Share
Cancel

Want to share it with your friends too?

Facebook Whatsapp Twitter Linkedin
Copied

Love India news?

Subscribe to stay updated.

India Thumbnail
India News Business News World News Politics News Sports News Science News Entertainment News Auto News Lifestyle News Inspirational News
Career News Bengaluru News Delhi News Mumbai News Bharti Airtel Mukesh Ambani Indian Premier League Samsung Virat Kohli Rohit Sharma
Cricket News YouTube Hollywood News WhatsApp Bollywood News Real Madrid ISRO Yoga Honda Batman
Football News BMW Vaccine Reliance Jio OPPO Food News, Healthy Recipes Apple Royal Challengers Bangalore Toyota Fashion Tips
Mercedes Sidharth Malhotra Isha Ambani India Vs England Cricket OnePlus Mobiles Android TV Smart TV Marvel Comics Avengers Neha Kakkar
Big Bang Theory X-Men TATA Royal Enfield
About Us Privacy Policy Terms & Conditions Contact Us News Reviews News Archive Topics Archive Find Cricket Statistics
Follow us on
Facebook Twitter Linkedin Youtube
All rights reserved © NewsBytes 2021